ArticleFrontiers in immunology2018
S100A4
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 86 citations in OpenAlex.
- Immune dysregulation in the prostates of C57BL/6The Journal of pathology · 2026Article
- Recent advances in pulmonary fibrosis: from lung surfactant to the immune connection.Respiratory research · 2026Review
- Review
- Monocyte-mediated mechanisms in idiopathic pulmonary fibrosis: opportunities for early intervention.Apoptosis : an international journal on programmed cell death · 2026Review
- Single-Cell and Spatial Transcriptomics Identify the Mono-S100A4 Subset Associated with Sepsis-Induced Lung Injury via the MIF-(CD74+CD44) Axis.Journal of inflammation research · 2026Article
- Proteomic insights into vaginal mesh complications and treatment targets.Acta biomaterialia · 2025Article
- S100A4/FSP1: A Prognostic Marker and a Promising Target for Antitumor Therapy.International journal of molecular sciences · 2025Review
- Downregulation of S100 calcium-binding A4 (S100A4) ameliorates hepatic fibrosisEuropean journal of histochemistry : EJH · 2025Article
- Review
- A review on clinical implications of S100 proteins in lung diseases.Frontiers in medicine · 2025Review
- Citrullinated and malondialdehyde-acetaldehyde-modified fibrinogen activates macrophages and promotes profibrotic responses in human lung fibroblasts.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Immunobiology of pulmonary fibrosis.Frontiers in immunology · 2025Review
- The multi-faceted immune modulatory role of S100A4 in cancer and chronic inflammatory disease.Frontiers in immunology · 2025Review
- Antifibrotic effect of disulfiram on bleomycin-induced lung fibrosis in mice and its impact on macrophage infiltration.Scientific reports · 2024Article
- Exploring the molecular mechanisms and shared potential drugs between rheumatoid arthritis and arthrofibrosis based on large language model and synovial microenvironment analysis.Scientific reports · 2024Article
- Dexamethasone treatment influences tendon healing through altered resolution and a direct effect on tendon cells.Scientific reports · 2024Article
- Acute lung injury: a view from the perspective of necroptosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Single-cell RNA sequencing to explore cancer-associated fibroblasts heterogeneity: "Single" vision for "heterogeneous" environment.Cell proliferation · 2024Review
- The role of macrophage polarization and cellular crosstalk in the pulmonary fibrotic microenvironment: a review.Cell communication and signaling : CCS · 2024Review
- S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.Rheumatology (Oxford, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Yanan LiKey Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Jing BaoDepartment of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
Yangyang BianMedical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ulrike ErbenKey Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Peigang WangKey Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Kun SongKey Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Shuangqing LiuKey Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Zhenzhen LiMedical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhancheng GaoDepartment of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
Zhihai QinKey Laboratory of Protein and Peptide Pharmaceuticals, CAS Center for Excellence in Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
First Affiliated Hospital of Zhengzhou University · CNChinese Academy of Sciences · CNInstitute of Biophysics · CNPeking University · CNUniversity of Chinese Academy of Sciences · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
S100A4, a calcium-binding protein, can promote pulmonary fibrosis
Indexed as
ActinsAnimalsBleomycinBronchoalveolar Lavage FluidCD11b AntigenCell LineDisease Models, AnimalFibroblastsHumansIdiopathic Pulmonary FibrosisLungMacrophages, AlveolarMiceMice, Inbred C57BLRAW 264.7 CellsS100 Calcium-Binding Protein A4ACTA2 protein, humanActinsBleomycinCD11b AntigenS100A4 protein, humanS100a4 protein, mouseS100 Calcium-Binding Protein A4fibroblastsmacrophagespulmonary fibrosisS100A4sphingosine-1-phosphate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.